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URINARY & KIDNEY DISEASES/DISORDERS—
Economic Outcomes
PRK1
ASSESSING PROVIDER TIME FOR ANAEMIA
MANAGEMENT OF DIALYSIS PATIENTS USING
TIME & MOTION METHODS:A MULTI-CENTRE
OBSERVATIONAL STUDY IN EUROPE
De Cock E1,Van Bellinghen L2, Standaert B2
1MEDTAP International, London, United Kingdom; 2Amgen
Europe, Brussels, Belgium
OBJECTIVE: Estimate the provider time allocated to the
management of anaemia with rHuEPO in dialysis centres
throughout Europe. METHOD: The same time and
motion protocol was used in nine dialysis centres in ﬁve
European countries (Netherlands, Germany, France,
Spain and Italy). Structured interviews with key person-
nel were used to obtain an overview of all rHuEPO
related activities performed by physician, nurse, health
auxiliaries, lab and pharmacy personnel. Strict start and
end points were deﬁned for frequent activities (n/week >
1). Time devoted to these activities was measured by a
trained centre nurse with a chronometer. Time devoted to
less frequent activities (n/week < 1) was estimated from
interviews. Nurse and physician time analysis by dialysis
centre is reported. To compare time measured across 
the different centres, activities were regrouped into three
main tasks for nurses (rHuEPO administration; blood
sampling; other rHuEPO management) and two for
physicians (anaemia monitoring and drug & blood 
prescription). RESULTS: Average time for rHuEPO 
management per session by nurse and physician com-
bined was 3min 52sec (Min: 1min 47sec; Max: 6min 
34sec). The observed time differences were explained by
the differences in tasks to be accomplished by nurses such
as getting drug and lab prescriptions, lab results, supplies,
billing the drug, getting the drug from pharmacy. Esti-
mated average time per year for rHuEPO management 
of 50 dialysis patients with 3 rHuEPO sessions per week
is therefore 503 hours ((3.87min ¥ 50 ¥ 3 ¥ 52)/60).
Switching to one session per week with darbepoetin alfa
(AranespTM) will gain an estimated 350 hours per year for
nurse and physician combined. CONCLUSION: With
fewer injections needed with AranespTM for anaemia man-
agement in dialyses centres, substantial time gain per year
may occur in each centre.
PRK2
COSTS OF CHRONIC KIDNEY DISEASE (CKD):
COST AND COMORBIDITY
Smith DH1, Gullion C1, Nichols G2, Keith D2,
Brown J2
1Kaiser Permanente Center for Health Research, Portland,
OR, USA; 2Kaiser Center for Health Research, Portland, OR,
USA
OBJECTIVES: We examined the incremental cost of
CKD over a 66-month period, and the contribution 
of CKD-related comorbidity to the cost of care.
METHODS: Using electronic medical record data at a
large HMO, we calculated inpatient, outpatient, phar-
macy and total costs for 13,796 cases and 13,796
matched (age and gender) controls. Cases were patients
whose glomerular ﬁltration rates (GFR, ml/min/1.72m2)
were <90 on two consecutive measurements (at least 90
days apart) in 1996. Cases were divided into stages 2, 3
and 4 based on new guidelines from the National Kidney
Foundation. Patients were followed until death, initiation
of renal replacement therapy (RRT), or July 1, 2001.
CKD-related comorbidities were identiﬁed (diabetes, con-
gestive heart failure, coronary artery disease, anemia and
hypertension) based on ICD9 codes. RESULTS: Patients
with CKD were 1.9 to 2.5 times more likely (depending
on stage) than controls to have been treated with pre-
scription drugs, had more outpatient visits (1.3 to 1.9
times more than controls, across stages), and had 1.8 to
3.1 more inpatient stays than did controls. CKD-related
comorbidities almost double the total cost of care for
both cases and controls, and cases with no CKD-related
comorbidities are about twice as expensive to manage as
controls with no CKD-related comorbidities. CONCLU-
SION: We found that CKD doubles costs to the health
care system, and that comorbidities related to CKD con-
tribute more to the cost of managing these patients than
does CKD alone. Future research in this area could be
usefully directed toward analyzing the clinical and eco-
nomic consequences of better managing patients with
CKD.
PRK3
BRANDED VS GENERIC CYCLOSPORINE IN 
DE-NOVO KIDNEY TRANSPLANTATION—
WHERE ARE THE COST SAVINGS?
Pirk O1, Schultes HJ2, Fricke FU1
1Fricke & Pirk GmbH, Nuremberg, Germany; 2Novartis
Pharma GmbH, Nuremberg, Germany
OBJECTIVE: Cyclosporine introduction for immunosup-
pressive therapy in the early 1980s has improved graft
survival fundamentally. In the last few years generic
cyclosporines, suggesting similar pharmacokinetics to
branded cyclosporines, were introduced in several
markets. The economic implication with respect to graft
survival rates using branded or generic cyclosporine is
described in the following for Germany. METHODS: The
Collaborative Transplant Study recently (2001) presented
a survey of all actively forwarded one-year-graft-survival
data for kidney transplantation, using either branded or
generic cyclosporine in de-novo transplantations between
1998 and 2000. With 16,800 patients in the branded and
nearly 400 in the generic arm the 10% increase in graft
loss in the generic arm was not statistically signiﬁcant but
clinically relevant. The cost analysis of kidney graft loss
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for each month during the ﬁrst year following transplan-
tation took into account only direct costs arising from
transplantectomy (€3,153, procedural rate plus daily 
hospital rate) and dialysis (€3,687 monthly, Kupsch et al.
1998). RESULTS: Based on these data, the average
annual costs of a graft loss are calculated. Consequently,
an average patient treated with cyclosporine brand med-
ication leads to additional annual costs of €4,239 due to
graft loss. In patients treated with a generic formulation
these costs amount to €7,832. The resulting cost dif-
ferential of €3,593 per year implies that a generic
cyclosporine formulation would have to be at least 61%
cheaper than a brand regimen (currently €5,675 p.a.) in
order to be at least cost neutral. CONCLUSION: Focus-
ing only on direct costs of graft loss not including e.g.
rescue medication, the above calculation is extremely con-
servative. Cost savings potentially achievable by means of
a generic treatment regimen will most likely be consumed
by signiﬁcant costs resulting from graft loss unless the
generic is more than 61% cheaper than brand medica-
tion. This ratio will worsen considerably if the costs for
retransplantation are taken into account.
PRK4
AN ECONOMIC MODEL OF UNSTABLE
BLADDER IN BELGIUM
Kurth H1, Pieters R2, Sloesen B3, Bhattacharyya S4,
Dhawan R4, Bentkover J1
1Innovative Health Solutions, Brookline, MA, USA; 2UROBEL
vzw, Gent, Belgium; 3Pharmacia Belgium, Diegem, Belgium;
4Pharmacia Corp, Peapack, NJ, USA
OBJECTIVE: An economic model was developed to 
estimate the comparative cost-effectiveness of treating
unstable bladder (UB) in Belgium with alternative drug
treatments and no treatment. The model uses a one-year
timeframe and the payer (e.g., Riziv/INAMI, Sickness
funds) perspective. METHODS: The study population
included patients seeking UB treatment and was divided
into successfully treated patients (STP) and patients
failing treatment (PFT). The percentage of STP was cal-
culated from clinical efﬁcacy adjusted by annual persis-
tency. For each group of patients, direct and indirect costs
were identiﬁed, including costs for drugs, incontinence
pads, physician visits, lab tests/diagnostics, and associated
comorbidities. Resource utilization and costs were
obtained from literature, the National Health Insurance
System, Ofﬁcial Public Price Ministry Economic
Affairs/Pharmaceutical Tariﬁcation, clinical trials, and
expert medical panels. RESULTS: The prevalence of UB
sufferers in Belgium was estimated to be 3% in 2002
(approximately 303,000 people), with only 30% of those
patients seeking treatment (approximately 1% of the
Belgian population). STP used fewer pads per day, visited
physicians less frequently, had fewer lab tests/diagnostics,
and experienced fewer comorbidities than PFT. Cost
drivers in the model were comorbidities and physician
visits. Tolterodine sustained-release (TSR) had compara-
ble efﬁcacy to oxybutynin, but persistence on therapy was
higher for TSR. Therefore, effectiveness was higher for
TSR versus oxybutynin (37% for TSR, 10% for oxybu-
tynin). Effectiveness was considered 0% for no treatment.
Cost per STP was €1,167 for TSR and €2,181 for oxy-
butynin. Sensitivity analyses varying efﬁcacy and persis-
tency by 10% still resulted in a lower cost per STP for
TSR. TSR had an incremental cost-effectiveness of €816.
The “no treatment” group demonstrated the highest non-
drug costs while providing no efﬁcacy. CONCLUSION:
Tolterodine sustained-release is a more cost-effective
treatment than oxybutynin in treating UB as measured by
cost per successfully treated patient in Belgium.
PRK5
A STRAIGHTFORWARD COST-EFFECTIVENESS
ANALYSIS OF LONG-ACTING TREATMENTS
FOR OVERACTIVE BLADDER: CAN IT BE THIS
SIMPLE?
Noe LL1, Becker RV1, Chen DM1,Williamson TE2
1Ovation Research Group, Highland Park, IL, USA; 2Pharmacia,
Peapack, NJ, USA
OBJECTIVES: Several researchers have estimated the
cost-effectiveness (CE) of long-acting forms of tolterodine
(TOL) and oxybutynin (OXY) in overactive bladder
(OAB). Typically, it’s assumed that effectively treated
patients consume fewer resources, including incontinence
pads, physician visits, laboratory tests, and costs related
to comorbid conditions. Claims analyses have shown a
link between the presence of OAB and higher medical
costs; however, no prospective studies have evaluated the
effect of treatment on resource consumption, and drug
acquisition cost (DAC) continues to be the focus for many
decision-makers. A head-to-head patient outcome trial
comparing TOL and OXY was recently completed, 
the Antimuscarinic Clinical Effectiveness Trial (ACET);
however, resource consumption wasn’t collected. Our
objective was to determine the CE of TOL 4mg and OXY
10mg based on DAC and effectiveness data from ACET.
METHODS: The primary effectiveness endpoint in
ACET was patient perception of improvement in their
bladder condition after eight weeks of treatment. Results
showed that 70% of TOL patients and 60% of OXY
patients reported improvement in their bladder condition
at 8 weeks. Dropout rates were 11.6% and 20.5% for
TOL and OXY, respectively. We assumed dropouts com-
pleted four weeks of treatment. The daily AWP cost of
TOL 4mg and OXY 10mg was $2.7967 and $2.6875,
respectively. RESULTS: For every 100 patients treated
with TOL and OXY, DAC is $14,752.98 and
$13,507.38, respectively. The cost per effectively treated
patient for TOL is $210.76 and $225.12 for OXY. The
incremental CE for TOL is $124.56 per additional effec-
tively treated patient. CONCLUSIONS: When only DAC
is considered, TOL is more cost-effective than OXY. If
effectively treated patients do consume fewer resources,
then the CE of TOL should be even better. Determining
